Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1961 1
1978 1
1983 1
1985 2
1986 1
1990 1
1991 4
1992 2
1993 1
1994 1
1995 2
1996 3
1997 1
1998 3
1999 2
2000 2
2001 9
2002 5
2003 2
2005 2
2006 1
2007 1
2008 1
2012 1
2013 2
2014 1
2015 5
2016 2
2017 1
2018 2
2019 6
2020 5
2021 3
2022 6
2023 7
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.
Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A. Nishio S, et al. Among authors: kado n. J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118. J Gynecol Oncol. 2025. PMID: 40590327 Free PMC article. Clinical Trial.
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Hamauchi S, Yasui H, Yokota T, Tsushima T, Fushiki K, Naito T, Ono A, Kado N, Onozawa Y, Murakami H, Takahashi T, Hirashima Y, Mori K, Yamazaki K. Hamauchi S, et al. Among authors: kado n. Invest New Drugs. 2024 Dec;42(6):655-663. doi: 10.1007/s10637-024-01480-w. Epub 2024 Oct 26. Invest New Drugs. 2024. PMID: 39460855 Clinical Trial.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Kitawaki J, et al. Among authors: kado n. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):149-55. doi: 10.1016/s0960-0760(02)00260-1. J Steroid Biochem Mol Biol. 2002. PMID: 12650711 Review.
[Hormone responsiveness of endometriosis].
Kitawaki J, Ishihara H, Koshiba H, Kusuki I, Kado N, Honjo H. Kitawaki J, et al. Among authors: kado n. Nihon Rinsho. 2001 Jan;59 Suppl 1:70-6. Nihon Rinsho. 2001. PMID: 11235181 Review. Japanese. No abstract available.
Radioimmunoassay for benzo[a]pyrene.
Kado NY, Wei ET. Kado NY, et al. J Natl Cancer Inst. 1978 Jul;61(1):221-5. doi: 10.1093/jnci/61.1.221. J Natl Cancer Inst. 1978. PMID: 276629
92 results